00:00 It's Benzinga and here's what's on the block.
00:02 PepsiCo CEO Ramon LaGuarta stated that the company has not been significantly affected
00:07 by weight loss or diabetes drugs, but they are monitoring their potential impact.
00:12 The popularity of semaglut2 drugs in the US has increased, benefiting the drug manufacturer
00:18 Novo Nordisk.
00:19 PepsiCo and other food companies are offering smaller sizes and healthier options in anticipation
00:24 of potential changes in consumer preferences.
00:27 PepsiCo's portfolio strategy includes reducing fat, sugar and salt in selling products in
00:32 smaller packages.
00:34 The company has seen success with reduced sizes and price hikes, leading to higher revenue.
00:40 PepsiCo has raised its full-year forecast and its shares have increased, sales for Gatorade,
00:44 Bubbly and sodas have risen, and Pepsi plans to relaunch the Baja Blast soda.
00:49 For all things money, visit Benzinga.com.
00:51 [BLANK_AUDIO]
Comments